格隆汇3月29日丨东瑞制药(02348.HK)公布年度业绩，2024年度，集团年度录得收入约人民币12.31亿元，较二2024年增加约16.1%。母公司拥有人应占溢利约人民币2.14亿元，比2024年减少62.1%。因2024年母公司拥有人应占溢利含出售于集团账面值为零元的35%康融东方股权录得净收益约人民币2.78亿元所致；如撇除以上非经常性溢利约人民币3.67亿元及出售股权前需分担的康融东方亏损人民币369.6万元因素，2024年母公司拥有人经营性溢利为人民币2.02亿元，则2025年较2024年增加6.1%。拟派末期息每股0.048港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.